Literature DB >> 7591152

Disruption of the murine interleukin-4 gene inhibits disease progression during Leishmania mexicana infection but does not increase control of Leishmania donovani infection.

A Satoskar1, H Bluethmann, J Alexander.   

Abstract

The growths of both cutaneous leishmaniasis and visceral leishmaniasis caused by Leishmania mexicana and Leishmania donovani, respectively, were measured in interleukin-4 (IL-4) knockout mice (IL-4-/-) and compared with those of similarly infected wild-type (IL-4+/+) control mice. While large, nonhealing, cutaneous lesions containing large numbers of parasites developed in IL-4+/+ mice subcutaneously infected with 5 x 10(6) L. mexicana amastigotes in the shaven rump, in IL-4-/- mice no lesions whatsoever developed and parasites were difficult to detect. Systemic spread and metastasis were also noted in IL-4+/+ but not IL-4-/- mice. In contrast, IL-4-/- mice infected intravenously with 10(7) L. donovani amastigotes were found to have consistently higher parasite burdens in their livers throughout infection than did their wild-type counterparts. However, these differences were only significant at 15 days postinfection. While the results reported here pertaining to L. donovani largely support previous studies, those related to L. mexicana provide new observations. The immunological responses of IL-4-/- and IL-4+/+ mice infected with L. mexicana were, therefore, examined both in vivo and in vitro. Although neither IL-4-/- nor IL-4+/+ mice infected with L. mexicana produced parasite-specific immunoglobulin G2a antibodies, IL-4+/+ mice, unlike IL-4-/- mice, developed significant immunoglobulin G1 antibody titers as infection progressed, indicating a Th2-influenced response in wild-type mice. In addition, IL-4-/- mice, unlike IL-4+/+ mice, developed a significant delayed-type hypersensitivity response, indicating a Th1-influenced response in IL-4-/- mice. Following in vitro stimulation, splenocytes from IL-4+/+ mice infected with L. mexicana displayed significantly higher antigen-specific proliferative responses than did IL-4-/- mice. However, gamma interferon production as measured from the supernatants of the in vitro splenocyte cultures of IL-4-/- mice was significantly higher than that from IL-4+/+ mice. This again would indicate a predominantly Th1-influenced response in the absence of a Th2 response in IL-4-/- mice infected with L. mexicana. On the other hand, at the same time point, draining lymph node cells from IL-4+/+ mice produced significantly higher quantities of IL-5 than did those from IL-4-/- mice following in vitro antigenic stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7591152      PMCID: PMC173701          DOI: 10.1128/iai.63.12.4894-4899.1995

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  26 in total

Review 1.  The interaction of Leishmania species with macrophages.

Authors:  J Alexander; D G Russell
Journal:  Adv Parasitol       Date:  1992       Impact factor: 3.870

Review 2.  Induction of Th1 and Th2 CD4+ subsets during murine Leishmania major infection.

Authors:  R M Locksley; F P Heinzel; B J Holaday; S S Mutha; S L Reiner; M D Sadick
Journal:  Res Immunol       Date:  1991-01

Review 3.  Functional heterogeneity of CD4+ T cells in leishmaniasis.

Authors:  F Y Liew
Journal:  Immunol Today       Date:  1989-02

4.  Influence of Lsh, H-2, and an H-11-linked gene on visceralization and metastasis associated with Leishmania mexicana infection in mice.

Authors:  M Roberts; J Alexander; J M Blackwell
Journal:  Infect Immun       Date:  1989-03       Impact factor: 3.441

5.  Genetic analysis of Leishmania mexicana infection in mice: single gene (Scl-2) controlled predisposition to cutaneous lesion development.

Authors:  M Roberts; J Alexander; J M Blackwell
Journal:  J Immunogenet       Date:  1990 Feb-Apr

6.  Production of interferon gamma, interleukin 2, interleukin 4, and interleukin 10 by CD4+ lymphocytes in vivo during healing and progressive murine leishmaniasis.

Authors:  F P Heinzel; M D Sadick; S S Mutha; R M Locksley
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-15       Impact factor: 11.205

7.  Differential production of Th1- and Th2-derived cytokines does not determine the genetically controlled or vaccine-induced rate of cure in murine visceral leishmaniasis.

Authors:  P M Kaye; A J Curry; J M Blackwell
Journal:  J Immunol       Date:  1991-04-15       Impact factor: 5.422

8.  Cytokine interactions in experimental cutaneous leishmaniasis. Interleukin 4 synergizes with interferon-gamma to activate murine macrophages for killing of Leishmania major amastigotes.

Authors:  C Bogdan; S Stenger; M Röllinghoff; W Solbach
Journal:  Eur J Immunol       Date:  1991-02       Impact factor: 5.532

9.  Murine hepatic accessory cells support the proliferation of Th1 but not Th2 helper T lymphocyte clones.

Authors:  D B Magilavy; F W Fitch; T F Gajewski
Journal:  J Exp Med       Date:  1989-09-01       Impact factor: 14.307

10.  Reciprocal expression of interferon gamma or interleukin 4 during the resolution or progression of murine leishmaniasis. Evidence for expansion of distinct helper T cell subsets.

Authors:  F P Heinzel; M D Sadick; B J Holaday; R L Coffman; R M Locksley
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

View more
  40 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

2.  Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.

Authors:  P C Melby; J Yang; W Zhao; L E Perez; J Cheng
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

3.  The Potent ITK/BTK Inhibitor Ibrutinib Is Effective for the Treatment of Experimental Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Sanjay Varikuti; Greta Volpedo; Noushin Saljoughian; Omar M Hamza; Gregory Halsey; Nathan M Ryan; Bren E Sedmak; Gabriella R Seidler; Tracey L Papenfuss; Steve Oghumu; Abhay R Satoskar
Journal:  J Infect Dis       Date:  2019-01-29       Impact factor: 5.226

Review 4.  Role of chemokines in regulation of immunity against leishmaniasis.

Authors:  Steve Oghumu; Claudio M Lezama-Dávila; Angelica P Isaac-Márquez; Abhay R Satoskar
Journal:  Exp Parasitol       Date:  2010-03-03       Impact factor: 2.011

5.  A Novel Sterol Isolated from a Plant Used by Mayan Traditional Healers Is Effective in Treatment of Visceral Leishmaniasis Caused by Leishmania donovani.

Authors:  Gaurav Gupta; Kevin J Peine; Dalia Abdelhamid; Heidi Snider; Andrew B Shelton; Latha Rao; Sainath R Kotha; Andrew C Huntsman; Sanjay Varikuti; Steve Oghumu; C Benjamin Naman; Li Pan; Narasimham L Parinandi; Tracy L Papenfuss; A Douglas Kinghorn; Eric M Bachelder; Kristy M Ainslie; James R Fuchs; Abhay R Satoskar
Journal:  ACS Infect Dis       Date:  2015-09-21       Impact factor: 5.084

Review 6.  Cytokines and their STATs in cutaneous and visceral leishmaniasis.

Authors:  Hannah E Cummings; Rashmi Tuladhar; Abhay R Satoskar
Journal:  J Biomed Biotechnol       Date:  2010-03-15

7.  Comparison of BCG, MPL and cationic liposome adjuvant systems in leishmanial antigen vaccine formulations against murine visceral leishmaniasis.

Authors:  Rajesh Ravindran; Sudipta Bhowmick; Amrita Das; Nahid Ali
Journal:  BMC Microbiol       Date:  2010-06-24       Impact factor: 3.605

8.  A Leishmania infantum cytosolic tryparedoxin activates B cells to secrete interleukin-10 and specific immunoglobulin.

Authors:  Sofia Menezes Cabral; Ricardo Leal Silvestre; Nuno Moreira Santarém; Joana Costa Tavares; Ana Franco Silva; Anabela Cordeiro-da-Silva
Journal:  Immunology       Date:  2007-11-17       Impact factor: 7.397

9.  Both interleukin-4 (IL-4) and IL-4 receptor alpha signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity.

Authors:  Simona Stäger; James Alexander; K Christine Carter; Frank Brombacher; Paul M Kaye
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

10.  Immunoenhancement combined with amphotericin B as treatment for experimental visceral leishmaniasis.

Authors:  Henry W Murray; Elaine B Brooks; Jennifer L DeVecchio; Frederick P Heinzel
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.